The Association of Kidney Function and Inflammatory Biomarkers with Epithelial Ovarian Cancer Risk

被引:2
|
作者
Hathaway, Cassandra A. [1 ,2 ,8 ]
Townsend, Mary K. [1 ]
Sklar, Elliot M. [2 ]
Thomas-Purcell, Kamilah B. [2 ]
Terry, Kathryn L. [3 ,4 ,5 ]
Trabert, Britton [6 ,7 ]
Tworoger, Shelley S. [1 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
[2] Nova Southeastern Univ, Dr Pallavi Patel Coll Hlth Care Sci, Ft Lauderdale, FL USA
[3] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA
[4] Harvard Med Sch, Boston, MA USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[6] Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA
[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Epidemiol, 13131 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
C-REACTIVE PROTEIN; GLOMERULAR-FILTRATION-RATE; ORAL-CONTRACEPTIVES; DISEASE; CREATININE; MARKERS; HEALTH; CKD; PROGRESSION; DECLINE;
D O I
10.1158/1055-9965.EPI-23-0543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: One of the mechanisms of ovarian tumorigenesis is through inflammation. Kidney dysfunction is associated with increased inflammation; thus, we assessed its relationship with ovarian cancer risk.Methods: In prospectively collected samples, we evaluated the association of kidney function markers and C-reactive protein (CRP) with ovarian cancer risk in the UK Biobank. We used multivariable-adjusted Cox proportional hazards models to evaluate quartiles of serum and urine markers with ovarian cancer risk overall and by histology. We assessed effect modification by CRP (<= 3.0, >3.0 mg/L).Results: Among 232,908 women (1,110 ovarian cancer cases diagnosed from 2006-2020), we observed no association between estimated glomerular filtration rate and ovarian cancer risk (Q4 vs. Q1: HR, 1.00; 95% confidence intervals, 0.83-1.22). Potassium was associated with endometrioid (Q4 vs. Q1: 0.33, 0.11-0.98) and clear cell (4.74, 1.39-16.16) tumors. Poor kidney function was associated with a nonsignificant increase in ovarian cancer risk among women with CRP>3.0 mg/L (e.g., uric acid Q4 vs. Q1; 1.23, 0.81-1.86), but not CRP <= 3.0 mg/L (0.83, 0.66-1.05). Other associations did not vary across CRP categories.Conclusions: Kidney function was not clearly associated with ovarian cancer risk. Larger studies are needed to evaluate possible histology specific associations. Given the suggestive trend for increased ovarian cancer risk in women with poor kidney function and high CRP, future work is needed, particularly in populations with a high prevalence of inflammatory conditions.Impact: This study provided the first evaluation of markers of kidney function in relation to ovarian cancer risk.
引用
收藏
页码:1451 / 1457
页数:7
相关论文
共 50 条
  • [1] Inflammation-related biomarkers and risk of epithelial ovarian cancer
    Poole, Elizabeth M.
    Lee, I. M.
    Buring, Julie E.
    Hankinson, Susan E.
    Tworoger, Shelley S.
    CANCER RESEARCH, 2012, 72
  • [2] PELVIC INFLAMMATORY DISEASE AND THE RISK OF EPITHELIAL OVARIAN-CANCER
    RISCH, HA
    HOWE, GR
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 141 (11) : S24 - S24
  • [3] PELVIC INFLAMMATORY DISEASE AND THE RISK OF EPITHELIAL OVARIAN-CANCER
    RISCH, HA
    HOWE, GR
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1995, 4 (05) : 447 - 451
  • [4] Epigenetic biomarkers in epithelial ovarian cancer
    Gloss, Brian S.
    Samimi, Goli
    CANCER LETTERS, 2014, 342 (02) : 257 - 263
  • [5] ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium
    Elizabeth M. Poole
    Margaret A. Gates
    Brigit A. High
    Stephen J. Chanock
    Daniel W. Cramer
    Julie M. Cunningham
    Brooke L. Fridley
    Simon A. Gayther
    Ellen L. Goode
    Edwin S. Iversen
    Jolanta Lissowska
    Rachel T. Palmieri Weber
    Paul D. P. Pharoah
    Catherine M. Phelan
    Susan J. Ramus
    Joellen M. Schildkraut
    Rebecca Sutphen
    Ya-Yu Tsai
    Jonathan Tyrer
    Robert A. Vierkant
    Nicolas Wentzensen
    Hannah P. Yang
    Kathryn L. Terry
    Shelley S. Tworoger
    Cancer Causes & Control, 2012, 23 : 1805 - 1810
  • [6] ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium
    Poole, Elizabeth M.
    Gates, Margaret A.
    High, Brigit A.
    Chanock, Stephen J.
    Cramer, Daniel W.
    Cunningham, Julie M.
    Fridley, Brooke L.
    Gayther, Simon A.
    Goode, Ellen L.
    Iversen, Edwin S.
    Lissowska, Jolanta
    Weber, Rachel T. Palmieri
    Pharoah, Paul D. P.
    Phelan, Catherine M.
    Ramus, Susan J.
    Schildkraut, Joellen M.
    Sutphen, Rebecca
    Tsai, Ya-Yu
    Tyrer, Jonathan
    Vierkant, Robert A.
    Wentzensen, Nicolas
    Yang, Hannah P.
    Terry, Kathryn L.
    Tworoger, Shelley S.
    CANCER CAUSES & CONTROL, 2012, 23 (11) : 1805 - 1810
  • [7] Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium
    Babic, Ana
    Harris, Holly R.
    Vitonis, Allison F.
    Titus, Linda J.
    Jordan, Susan J.
    Webb, Penelope M.
    Risch, Harvey A.
    Rossing, Mary Anne
    Doherty, Jennifer A.
    Wicklund, Kristine
    Goodman, Marc T.
    Modugno, Francesmary
    Moysich, Kirsten B.
    Ness, Roberta B.
    Kjaer, Susanne K.
    Schildkraut, Joellen
    Berchuck, Andrew
    Pearce, Celeste L.
    Wu, Anna H.
    Cramer, Daniel W.
    Terry, Kathryn L.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (03) : 460 - 469
  • [8] The role of biomarkers in the management of epithelial ovarian cancer
    Yang, Wei-Lei
    Lu, Zhen
    Bast, Robert C., Jr.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2017, 17 (06) : 577 - 591
  • [9] Association between Ambient Ultraviolet Radiation and Risk of Epithelial Ovarian Cancer
    Tran, Bich
    Jordan, Susan J.
    Lucas, Robyn
    Webb, Penelope M.
    Neale, Rachel
    CANCER PREVENTION RESEARCH, 2012, 5 (11) : 1330 - 1336
  • [10] Recent advances in the biomarkers for epithelial ovarian cancer
    Kim, Yun Hwan
    Kim, Seung Cheol
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2011, 22 (04) : 219 - 221